SynthesisNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2025
Clinical features of recurrent MOG antibody-associated cortical encephalitis in adults.
Synthesis in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical characteristics of MOG antibody-positive anti-NMDAR encephalitis: a single-center retrospective study.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
objectiveTo clarify the clinical features of recurrent myelin oligodendrocyte glycoprotein antibody-associated cortical encephalitis (MOGCE) in adults.
methodsWe present an adult case of recurrent MOGCE and summarize the clinical symptoms, imaging findings, treatment and prognosis of this phenotype as per a systematic review of the literature.
resultsWe identified 9 adult patients with recurrent MOGCE. The mean age was 32 years, and 5/9 were male. Median time to recurrence was 6 months (range 2-36 months). The most common presentations of the first attack were headache (9/9), fever (8/9) and seizure (5/9). In most patients (6/9), presentations of recurrent attacks were different than those of the first attack. Relapses may affect more areas than the first attack, such as spine, brainstem, grey matter, and basal ganglia. All patients were seropositive for MOG antibodies during the first or second attack, with antibody titers ranging from 1:10 to 1:100. CSF white blood cell count and total protein were elevated in 6/9 patients. On MRI, 4/9 showed bilateral FLAIR hyperintense lesions, while 5/9 had unilateral lesions. Most patients demonstrated a positive response to treatment, and maintenance immunotherapy was added upon relapse.
conclusionThe clinical presentation of recurrent MOGCE is atypical, and most patients had different symptoms upon recurrence compared to the first episode. Factors contributing to the likelihood of disease recurrence remain unclear. Most recurrent MOGCE patients respond well to immunotherapy, and require long-term immunotherapy after recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.